Miraqules, a Bengaluru-based biotech startup, is set to showcase its innovative blood clotting technology at TechCrunch Disrupt 2025, taking place from October 27 to 29 in San Francisco. The company, co-founded by CEO Sabir Hossain, has developed a nanotechnology in powder form that replicates blood clotting proteins, potentially transforming trauma care. Hossain’s motivation for creating this product stems from a personal experience; a near-fatal accident years ago left his father on the brink of bleeding to death.
The blood clotting powder is designed to produce fibrous compounds rapidly at room temperature, enabling it to absorb blood quickly upon application. “This is a product that will give you feedback instantly,” Hossain explained. “If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes.”
### Journey from Concept to Reality
Hossain’s journey into biotechnology began during his graduate studies in biomedical engineering. While working in a research lab focused on biomaterials, he encountered challenges while attempting to create 3D structures for bone tissue growth. He humorously admitted, “I was really bad at that.” However, an unexpected breakthrough occurred when he ground dismantled particles from his experiments into a powder. This powder was tested by a team working on blood clotting solutions, resulting in a rapid clotting response within five to ten seconds.
The positive outcome of this experiment prompted Hossain to collaborate with his childhood friend, Mubeen Midda, to further develop the technology. Their goal was to move this promising innovation out of the lab while minimizing funding requirements. Since its inception, Miraqules has successfully secured 11 patents across seven countries, including India, the United States, and Israel.
### Current Developments and Future Prospects
Miraqules’ technology is currently being piloted in a trauma care center in India, with the company anticipating regulatory clearance in the country within the next few months. Additionally, it aims to receive clearance from the U.S. Food and Drug Administration (FDA) in 2026. Hossain emphasized the importance of engaging with the FDA early in the process, stating, “One thing we did from the beginning, we directly went to the U.S. FDA. We tried to get their feedback on what other necessary things we need to do to get this product approved.”
Impressively, Miraqules has achieved these milestones with less than $700,000 in capital raised, primarily from grants. Looking ahead, the company plans to ramp up deployment and pilot programs in the coming year. They have already attracted interest from ten different hospital chains in India and the Israeli Defense Forces.
As Miraqules prepares to present its breakthrough technology at TechCrunch Disrupt 2025, the event promises to be a significant platform for startups, featuring over 300 showcasing companies and more than 200 sessions led by industry leaders. Those interested in learning more about Miraqules and other innovative startups are encouraged to attend the event to make valuable connections and gain insights into the future of technology and healthcare.
